PALVELLA THERAPEUTICS, INC. cotiza a 134.38 USD y tiene una capitalización bursátil de $1.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-1.52 | $-1.20 | $-1.08 |
| Estimado | $-1.74 | $-1.15 | $-0.93 | $-0.91 |
| Sorpresa | — | -32.2% | -29.0% | -18.7% |
| Métrica | PVLA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -149.1% | -40.4% | -108.7% |
| ROA | -70.0% | -32.0% | -38.0% |
| Current Ratio | 5.20 | 2.84 | +2.36 |
| Debt / Equity | — | 0.28 | — |